The combination of GLP-1 receptor agonist weight loss injections and sertraline is generally considered safe, with no direct pharmacological contraindication between these medication classes
Even individuals with Fitzpatrick Type I-II skin (naturally very fair) achieve noticeable pigmentation
Oral GLP-1 weight loss medication Orfoglipron (Eli Lilly) is nearing an FDA decision with available expect mid-2026 Clinical trials show meaningful results: 12-16% 1,2 average weight loss, which is slightly less than injectables Side effects are similar: mostly gastrointestinal, such as nausea or diarrhea, typically improving over 23 months
Topical GHK-Cu is generally well tolerated, but some people may experience mild scalp irritation, redness, itching, or contact dermatitis
A pioneering study of Lam et al
Muscle loss accelerates for women as they age, resulting in cascading symptoms like fatigue and weight gain